Sinsin Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Sinsin Pharmaceutical makes over-the-counter pain-relief patches, adhesive medicated plasters worn on the skin to ease muscle, joint, and nerve pain, along with liquid and spray formats, insect-repellent products, corn-removal treatments, ointments, and bandages.
Listed on KOSDAQ, Korea's small-cap board, it supplies pharmacies and wholesale drug distributors, with pharmacies accounting for the largest share of its revenue. Patch and fever-reducing patch products are also shipped to markets across Southeast Asia, broader Asia, and Europe.
Summary is AI-generated and may contain errors · figures from DART filings
The company operates sales branches in major cities nationwide and maintains direct trading relationships with tens of thousands of retail pharmacies across Korea.
Sinsin Pharmaceutical in five facts
What does Sinsin Pharmaceutical do?
Sinsin Pharmaceutical makes over-the-counter pain-relief patches, adhesive medicated plasters worn on the skin to ease muscle, joint, and nerve pain, along with liquid and spray formats, insect-repellent products, corn-removal treatments, ointments, and bandages.
Where is Sinsin Pharmaceutical listed and in which sector?
Sinsin Pharmaceutical (Korean name: 신신제약) trades under KRX code 002800 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Sinsin Pharmaceutical?
Its market capitalisation was US$47.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Sinsin Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Sinsin Pharmaceutical reported revenue of US$85.9M, operating profit of US$8.1M and net income of US$7M, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was up 7.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Cash/in-kind dividend decision
Sinsin Pharmaceutical declared a cash dividend of US$0.05 per share.
Dividend · Feb 9 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Sinsin Pharmaceutical reported consolidated results for FY2025: revenue of US$78.5M (+6.9% year on year), operating profit of US$7.45M (+56.6% year on year) and net income of US$6.42M (+93.2% year on year).
Earnings · Feb 2